Although the role of HOPX in CRC is controversial (Yamashita et al. 2013; Dmitrieva-Posocco et al. 2022), the assumption that its activation could contribute to the progression of a subset of aggressive tumors is in agreement with the observation that high expression of HOPX is significantly associated with bad prognosis in CRC (overall survival Log Rank P value 8.6×10−3 in the TCGA colorectal cohort (Fig. 3D;, Liu and Zhang 2020). The gene discussed is HOPX; the disease is colorectal carcinoma.